Literature DB >> 8279445

Plasma thrombomodulin as a marker of vascular injuries in collagen vascular diseases.

S Ohdama1, S Takano, S Miyake, T Kubota, K Sato, N Aoki.   

Abstract

Thrombomodulin, a thrombin receptor on the vascular endothelial cell surface, is released into circulating blood. The plasma concentrations in patients with collagen vascular diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis, Sjögren's syndrome, systemic sclerosis, polymyositis and/or dermatomyositis (PM/DM), Behçet's disease, and Wegener's granulomatosis, were measured and compared with those of healthy persons. The mean plasma thrombomodulin concentrations in patients with juvenile rheumatoid arthritis, systemic sclerosis, PM/DM, Wegener's granulomatosis, and active states of SLE, rheumatoid arthritis, and Beçhet's disease were significantly higher than those in the control group. Patients with Wegener's granulomatosis showed the highest mean value. The mean values in patients with inactive states of the diseases and Sjögren's syndrome were not significantly different from the values in the control group. In cases of juvenile rheumatoid arthritis, systemic sclerosis, PM/DM, and Wegener's granulomatosis, patients with active interstitial pneumonitis or extensive pulmonary lesions frequently showed higher values of plasma thrombomodulin than those without overt pulmonary involvement. Elevated plasma thrombomodulin values were decreased along with amelioration of the diseases by treatment. These results may indicate that plasma thrombomodulin measurement may be helpful for evaluating vascular injury in patients with collagen diseases.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8279445     DOI: 10.1093/ajcp/101.1.109

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  13 in total

1.  Lupus anticoagulant and history of thrombosis are not associated with persistent endothelial cell activation in systemic lupus erythematosus.

Authors:  C J Frijns; R H Derksen; P G De Groot; A Algra; R Fijnheer
Journal:  Clin Exp Immunol       Date:  2001-07       Impact factor: 4.330

2.  Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis.

Authors:  A L Herrick; K Illingworth; A Blann; C R Hay; S Hollis; M I Jayson
Journal:  Ann Rheum Dis       Date:  1996-02       Impact factor: 19.103

3.  Evaluation of various endothelial biomarkers in ankylosing spondylitis.

Authors:  Ali Taylan; Ismail Sari; Didem L Kozaci; Yasar Yildiz; Safak Bilge; Isil Coker; Sergir Maltas; Necati Gunay; Nurullah Akkoc
Journal:  Clin Rheumatol       Date:  2011-05-10       Impact factor: 2.980

4.  Decrease in circulating endothelial cell adhesion molecule and thrombomodulin levels during oral iloprost treatment in rheumatoid arthritis patients: preliminary results.

Authors:  Michael W J Boehme; Ino K Gao; Cornelia Norden; Ernst-Martin Lemmel
Journal:  Rheumatol Int       Date:  2005-02-08       Impact factor: 2.631

5.  Analysis of correlations between selected endothelial cell activation markers, disease activity, and nailfold capillaroscopy microvascular changes in systemic lupus erythematosus patients.

Authors:  Mariusz Ciołkiewicz; Anna Kuryliszyn-Moskal; Piotr Adrian Klimiuk
Journal:  Clin Rheumatol       Date:  2009-11-12       Impact factor: 2.980

6.  Successful treatment of rheumatoid arthritis is associated with a reduction in serum sE-selectin and thrombomodulin level.

Authors:  Veli Cobankara; Düzgün Ozatli; Sedat Kiraz; Mehmet Akif Oztürk; Ihsan Ertenli; Tufan Türk; Sule Apras; Ibrahim C Haznedaroglu; Meral Calgüneri
Journal:  Clin Rheumatol       Date:  2004-06-19       Impact factor: 2.980

Review 7.  Laboratory evaluation of the inflammatory myopathies.

Authors:  L G Rider; F W Miller
Journal:  Clin Diagn Lab Immunol       Date:  1995-01

8.  Soluble thrombomodulin and antibodies to bovine glomerular endothelial cells in patients with Henoch-Schönlein purpura.

Authors:  M Fujieda; N Oishi; K Naruse; M Hashizume; K Nishiya; T Kurashige; K Ito
Journal:  Arch Dis Child       Date:  1998-03       Impact factor: 3.791

9.  IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines.

Authors:  D Carvalho; C O Savage; C M Black; J D Pearson
Journal:  J Clin Invest       Date:  1996-01-01       Impact factor: 14.808

10.  Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma).

Authors:  A Scheja; A Akesson; P Geborek; M Wildt; C B Wollheim; F A Wollheim; U M Vischer
Journal:  Arthritis Res       Date:  2001-02-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.